Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

22.56
-1.7800-7.31%
Pre-market: 22.560.00000.00%05:31 EST
Volume:1.76M
Turnover:40.46M
Market Cap:1.77B
PE:-12.49
High:24.40
Open:23.95
Low:22.32
Close:24.34
52wk High:36.26
52wk Low:2.86
Shares:78.66M
Float Shares:53.14M
Volume Ratio:1.72
T/O Rate:3.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8064
EPS(LYR):-2.2041
ROE:-59.22%
ROA:-34.41%
PB:5.77
PE(LYR):-10.24

Loading ...

BRIEF-Olema Pharmaceuticals Inc - Terminates ATM Prospectus For Common Stock Dated January 6, 2025 - SEC Filing

Reuters
·
Nov 19, 2025

Olema Oncology announces common stock and warrants offering, no amount given

TIPRANKS
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals (OLMA) Plunges 5.66% After-Hours Following ATM Prospectus Termination

Stock Track
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals Plunges 5.66% After-Hours: ATM Prospectus Termination and Short Seller Pressure

Stock Track
·
Nov 19, 2025

Olema Pharmaceuticals Terminates ATM Prospectus

TIPRANKS
·
Nov 19, 2025

Olema Pharmaceuticals Inc - Terminates Atm Prospectus for Common Stock Dated January 6, 2025 - SEC Filing

THOMSON REUTERS
·
Nov 19, 2025

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Dow Jones
·
Nov 19, 2025

Positive Outlook for Olema’s OPERA-02 Study Following Roche’s Successful Phase 3 Trial Results

TIPRANKS
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals Soars 139.79% Following Roche's Breast Cancer Study Success and JPMorgan's Bullish Stance

Stock Track
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals Soars 140% on JPMorgan Upgrade and Positive Industry News

Stock Track
·
Nov 19, 2025

Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential

TIPRANKS
·
Nov 19, 2025

Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 18, 2025

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Benzinga_recent_news
·
Nov 18, 2025

Olema Rocketed 167%, Triggering A Circuit Breaker, JPMorgan's Bullish Price Target Hike

Stock Track
·
Nov 18, 2025

Stock Track | Olema Pharmaceuticals Skyrockets 208.80% Pre-Market on JPMorgan's Bullish Price Target Hike

Stock Track
·
Nov 18, 2025

Olema Oncology price target raised to $32 from $29 at JPMorgan

TIPRANKS
·
Nov 18, 2025

Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Nov 11, 2025

Promising Developments and Strategic Collaborations Boost Olema Pharmaceuticals’ Buy Rating

TIPRANKS
·
Nov 11, 2025

Optimistic Buy Rating for Olema Pharmaceuticals Driven by Unique Phase III Trials and Promising Market Potential

TIPRANKS
·
Nov 11, 2025

Olema Pharmaceuticals Q3 EPS $(0.49) Misses $(0.45) Estimate

Benzinga
·
Nov 10, 2025